Literature DB >> 24986769

Bromodomains: pockets with therapeutic potential.

Kostas A Papavassiliou1, Athanasios G Papavassiliou2.   

Abstract

Intense interest in the complex biology of the bromodomain (BRD) protein modules has fueled the development of novel small molecule inhibitors that target the acetyl-lysine (KAc) binding pocket of the BRD. BRD inhibition has revealed exciting opportunities for treating a variety of maladies such as cancer, inflammation, obesity, cardiovascular disease, and neurological disorders. With five BRD inhibitors already in clinical trials, the BRD field seems to be rising to success.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  bromodomain inhibitor; bromodomain pocket; therapeutic target; transcriptional regulation

Mesh：

Substances：

Year:  2014        PMID： 24986769     DOI： 10.1016/j.molmed.2014.06.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  9 in total

Review 1.  Biological function and histone recognition of family IV bromodomain-containing proteins.

Authors:  Jonathan T Lloyd; Karen C Glass
Journal:  J Cell Physiol       Date:  2017-06-13       Impact factor: 6.384

Review 2.  Epigenetic mechanisms underlying the pathogenesis of neurogenetic diseases.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

3.  The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.

Authors:  Chiara Pastori; Philipp Kapranov; Clara Penas; Veronica Peschansky; Claude-Henry Volmar; Jann N Sarkaria; Amade Bregy; Ricardo Komotar; Georges St Laurent; Nagi G Ayad; Claes Wahlestedt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-25       Impact factor: 11.205

Review 4.  Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions.

Authors:  Mark N Polizzotto; Grace Chen; Randall L Tressler; Catherine Godfrey
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

5.  Structural insights into recognition of acetylated histone ligands by the BRPF1 bromodomain.

Authors:  Mulu Y Lubula; Brian E Eckenroth; Samuel Carlson; Amanda Poplawski; Maksymilian Chruszcz; Karen C Glass
Journal:  FEBS Lett       Date:  2014-09-30       Impact factor: 4.124

Review 6.  Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.

Authors:  Lei-lei Fu; Mao Tian; Xiang Li; Jing-jing Li; Jian Huang; Liang Ouyang; Yonghui Zhang; Bo Liu
Journal:  Oncotarget       Date:  2015-03-20

7.  Key drivers of biomedical innovation in cancer drug discovery.

Authors:  Margit A Huber; Norbert Kraut
Journal:  EMBO Mol Med       Date:  2015-01       Impact factor: 12.137

Review 8.  Long non-coding RNA in glioma: signaling pathways.

Authors:  Jia Shi; Bo Dong; Jiachao Cao; Yumin Mao; Wei Guan; Ya Peng; Suinuan Wang
Journal:  Oncotarget       Date:  2017-04-18

Review 9.  Genome-Based Classification and Therapy of Prostate Cancer.

Authors:  Arlou Kristina Angeles; Simone Bauer; Leonie Ratz; Sabine M Klauck; Holger Sültmann
Journal:  Diagnostics (Basel)       Date:  2018-09-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.